Form 4: 10x Genomics Director Sells Shares
Insider Transaction (Form 4)
Sarah A. Teichmann, a Director of 10x Genomics, Inc., sold 7,551 shares of common stock on August 13, 2026.
Summary
- Open-market sale: disposed of 5,278 Class A Common Stock at $57.29 ($302,377) on August 13, 2026; holds 30,331 after (Direct).
- Open-market sale: disposed of 2,273 Class A Common Stock at $57.15 ($129,902) on August 14, 2026; holds 28,058 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $432,279 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Sarah A. Teichmann — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-13 | Open-market sale | Class A Common Stock | 5,278 | $57 | $302.4K | 30,331 |
| 2026-08-14 | Open-market sale | Class A Common Stock | 2,273 | $57 | $129.9K | 28,058 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-13 | Open-market sale (5,278 shares) |
| 2026-08-14 | Open-market sale (2,273 shares) |
Keywords
insider transaction, Form 4, TXG, 10x Genomics, Inc., bearish, Sarah A. Teichmann
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.